Study on co-delivery of pemetrexed disodium and Bcl-2 siRNA by poly-γ-glutamic acid-modified cationic liposomes for the inhibition of NSCLC

References

• Oser MG, Niederst MJ, Sequist LV, et al. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16(4):165–172.
   PubMed Web of Science ®Google Scholar
• Mao YS, Yang D, He J, et al. Epidemiology of lung cancer. Surg Oncol Clin N Am. 2016;25(3):439–445.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454.
   PubMed Web of Science ®Google Scholar
• Han W, Shi L, Ren L, et al. A nanomedicine approach enables co-delivery of cyclosporin a and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer. Signal Transduct Target Ther. 2018;3(1):16–31.
   PubMedGoogle Scholar
• Micklem DR, Lorens JB. RNAi screening for therapeutic targets in human malignancies. Curr Pharm Biotechnol. 2007;8(6):337–343.
   PubMed Web of Science ®Google Scholar
• Rychahou PG, Jackson LN, Farrow BJ, et al. RNA interference: mechanisms of action and therapeutic consideration. Surgery. 2006;140(5):719–725.
   PubMed Web of Science ®Google Scholar
• Li L, Gu W, Chen J, et al. Co-delivery of siRNAs and anti-cancer drugs using layered double hydroxide nanoparticles. Biomaterials. 2014;35(10):3331–3339.
   PubMed Web of Science ®Google Scholar
• Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116(2):205–219.
   PubMed Web of Science ®Google Scholar
• Kelly PN, Strasser A. The role of bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 2011;18(9):1414–1424.
   PubMed Web of Science ®Google Scholar
• Letai A, Sorcinelli MD, Beard C, et al. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell. 2004;6(3):241–249.
   PubMed Web of Science ®Google Scholar
• Rahman MA, Amin AM, Wang D, et al. RRM2 regulates bcl-2 in head and neck and lung cancers: a potential target for cancer therapy. Clin Cancer Res. 2013;19(13):3416–3428.
   PubMed Web of Science ®Google Scholar
• Serasinghe MN, Missert DJ, Asciolla JJ, et al. Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAFV600E inhibition and can be targeted to reduce resistance. Oncogene. 2015;34(7):857–867.
   PubMed Web of Science ®Google Scholar
• Zhou M, Zhang X, Xu X, et al. Doxorubicin@bcl-2 siRNA core@shell nanoparticles for synergistic anticancer chemotherapy. ACS Appl Bio Mater. 2018;1(2):289–297.
   PubMedGoogle Scholar
• Mendonça LS, Moreira JN, Lima MP, et al. Co‐encapsulation of anti‐BCR‐ABL siRNA and imatinib mesylate in transferrin receptor‐targeted sterically stabilized liposomes for chronic myeloid leukemia treatment. Biotechnol Bioeng. 2010;107(5):884–893.
   PubMed Web of Science ®Google Scholar
• Chen AM, Zhang M, Wei D, et al. Co-delivery of doxorubicin and bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small. 2010;5(23):2673–2677.
   Web of Science ®Google Scholar
• Rollins KD, Lindley C. Pemetrexed: a multitargeted antifolate. Clin Ther. 2005;27(9):1343–1382.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Justice R, Pazdur R. Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. Oncologist. 2009;14(9):930–935.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Feng X, Li T, et al. Y. Metformin synergistic pemetrexed suppresses non‐small‐cell lung cancer cell proliferation and invasion in vitro. Cancer Med. 2017;6(8):1965–1975.
   PubMed Web of Science ®Google Scholar
• Gronberg BH, Bremnes RM, Flotten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(19):3217–3224.
   PubMed Web of Science ®Google Scholar
• Yan L, Zhang J, Lee CS, et al. Micro- and nanotechnologies for intracellular delivery. Small. 2015;10(22):4487–4504.
   Web of Science ®Google Scholar
• Mohammed A, Higashi T, Motoyama K, et al. In vitro and in vivo co-delivery of siRNA and doxorubicin by folate-PEG-appended dendrimer/glucuronylglucosyl-β-cyclodextrin conjugate. AAPS J. 2019;21(4):54.
   PubMed Web of Science ®Google Scholar
• Gupta V, Lourenço SP, Hidalgo IJ. Development of gene therapy vectors: remaining challenges. J Pharm Sci. 2021;110(5):1915–1920.
   PubMed Web of Science ®Google Scholar
• Wei J, Al-Dulaymi M, Badea I, et al. Cellular uptake and distribution of gemini surfactant nanoparticles used as gene delivery agents. AAPS J. 2019;21(5):98–109.
   PubMed Web of Science ®Google Scholar
• Lila AA, Ishida T. Liposomal delivery systems: design optimization and current applications. Biol Pharm Bull. 2017;40(1):1–10.
   PubMed Web of Science ®Google Scholar
• Templeton NS, Lasic DD. New directions in liposome gene delivery. Mol Biotechnol. 1999;11(2):175–180.
   PubMed Web of Science ®Google Scholar
• Yao Y, Su Z, Liang Y, et al. pH-sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery. Int J Nanomed. 2015;10(1):6185–6198.
   PubMedGoogle Scholar
• Zhang R, Wang SB, Chen AZ, et al. Codelivery of paclitaxel and small interfering RNA by octadecyl quaternized carboxymethyl chitosan-modified cationic liposome for combined cancer therapy. J Biomater Appl. 2015;30(3):351–360.
   PubMed Web of Science ®Google Scholar
• Liao ZX, Ho YC, Chen HL, et al. Enhancement of efficiencies of the cellular uptake and gene silencing of chitosan/siRNA complexes via the inclusion of a negatively charged poly(γ-glutamic acid). Biomaterials. 2010;31(33):8780–8788.
   PubMed Web of Science ®Google Scholar
• Liao ZX, Peng SF, Ho YC, et al. Mechanistic study of transfection of chitosan/DNA complexes coated by anionic poly(γ-glutamic acid). Biomaterials. 2012;33(11):3306–3315.
   PubMed Web of Science ®Google Scholar
• Zhang W, Kang X, Yuan B, et al. Nano-Structural effects on gene transfection: large, botryoid-shaped nanoparticles enhance DNA delivery via macropinocytosis and effective dissociation. Theranostics. 2019;9(6):1580–1598.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhu X, Wu S, et al. Fabrication and evaluation of a γ-PGA-based self-assembly transferrin receptor-targeting anticancer drug carrier. Int J Nanomedicine. 2018;13:7873–7889.
   PubMed Web of Science ®Google Scholar
• He K, Liu J, Gao Y, et al. Preparation and evaluation of stearylamine-bearing pemetrexed disodium-loaded cationic liposomes in vitro and in vivo. AAPS PharmSciTech. 2020;21(5):193–203.
   PubMed Web of Science ®Google Scholar
• Arranja AG, Pathak V, Lammers T, et al. Tumor-targeted nanomedicines for cancer theranostics. Pharmacol Res. 2017;115:87–95.
   PubMed Web of Science ®Google Scholar